JAK2/FLT3-IN-1

Request For Quotation
JAK2/FLT3-IN-1 Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: ChengDu TongChuangYuan Pharmaceutical Co.Ltd  
Tel: 028-83379370 13880556291
Email: tcy@tcypharm.com
Company Name: Chuzhou KeMail Chemical Technology Co., Ltd  
Tel: 0550-5196001 15000891977
Email: wj520wjxby@126.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com

JAK2/FLT3-IN-1 manufacturers

  • Flonoltinib
  • Flonoltinib pictures
  • 2026-07-30
  • CAS:2387765-27-5
  • Purity: 99.52%
  • Supply Ability: 10g
JAK2/FLT3-IN-1 Basic information
Product Name:JAK2/FLT3-IN-1
Synonyms:JAK2/FLT3-IN-1;JAK2/FLT3 IN 1,JAK-2/FLT3-IN-1,JAK2/FLT3IN1;Ethanol, 2-[[1-[2-fluoro-4-[[5-methyl-4-[1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]-4-piperidinyl]methylamino]-;Flonoltinib（JAK2/FLT3-IN-1）;2-((1-(2-fluoro-4-((4-(1-isopropyl-1H-pyrazol-4-yl)-5-methylpyrimidin-2-yl)amino)phenyl)piperidin-4-yl)(methyl)amino)ethan-1-ol;Flonoltinib
CAS:2387765-27-5
MF:C25H34FN7O
MW:467.59
EINECS:
Product Categories:JAK2/FLT3-IN-1
Mol File:2387765-27-5.mol
JAK2/FLT3-IN-1 Structure
JAK2/FLT3-IN-1 Chemical Properties
Boiling point 660.2±65.0 °C(Predicted)
density 1.26±0.1 g/cm3(Predicted)
pka14.74±0.10(Predicted)
form Solid
color White to off-white
Safety Information
MSDS Information
JAK2/FLT3-IN-1 Usage And Synthesis
UsesFlonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity[1].
in vivo

Flonoltinib (30 and 60 mg/kg/day; p.o.; for 14 days) exhibits significant antitumor effects[1].

Animal Model:NOD/SCID mouse models[1]
Dosage:30 and 60 mg/kg
Administration:Oral administration; daily; for 14 days
Result:Exhibited significant antitumor effects.
The tumor growth inhibitory rates (TGI) were respective 58% and 93% in the MV4-11-bearing mice model.
IC 50JAK2: 0.7 nM (IC50); FLT3: 4 nM (IC50); JAK1: 26 nM (IC50); JAK3: 39 nM (IC50)
References[1] Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31. DOI:10.1021/acs.jmedchem.9b01348
JAK2/FLT3-IN-1 Preparation Products And Raw materials
Tag:JAK2/FLT3-IN-1(2387765-27-5) Related Product Information
FLT3 Protein, HUMAN (T227M, HEK293, HIS) NA MonoMethyl auristatin E ANGIOTENSIN II, HUMAN Carbonyl cyanide 3-chlorophenylhydrazone Metformin